On April 14, 2026 Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, reported upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, held April 17–22, in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to present new data at AACR (Free AACR Whitepaper) that highlight both the strength of our ADC platform and the continued advancement of our pipeline," said Mohit Trikha, Ph.D., Chief Executive Officer, Kivu Bioscience. "KIVU-107 has the potential to be a best-in-class PTK7-targeted ADC, designed to overcome the tolerability challenges seen with earlier programs. Our second program, KIVU-305, expands our reach into CEACAM5, reinforcing our ability to develop differentiated ADCs with improved stability, tolerability and anti-tumor activity."
Poster Presentation Details
Title: KIVU-107: a clinical-stage, best-in-class PTK7 antibody-drug conjugate (ADC) with favorable PK and an improved tolerability profile
Session: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PT
Location: Section 10
Poster Number: 5649
KIVU-107 is an ADC targeting protein tyrosine kinase 7 (PTK7), a validated oncology target associated with tumor-initiating cells and overexpressed across multiple solid tumors. A Phase 1 clinical trial in patients with advanced solid tumors is ongoing (NCT07229313).
Title: Preclinical efficacy and safety of KIVU-305, a novel CEACAM5-targeting antibody-drug conjugate (ADC) for colorectal cancer
Session Track: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PT
Location: Section 10
Poster Number: 5648
KIVU-305 is a next-generation ADC targeting CEACAM5, a well-validated antigen highly expressed in colorectal, pancreatic, gastric and lung cancers. While earlier CEACAM5-targeted ADCs established clinical feasibility, their impact has been limited by efficacy at tolerable doses, underscoring the need for improved linker-payload design. KIVU-305 is designed to address these challenges, with a Phase 1 clinical trial in patients with advanced solid tumors planned for 2026.
(Press release, Kivu Bioscience, APR 14, 2026, View Source [SID1234664378])